Objectif
The BERENICE consortium is aiming at providing a new and cost-effective solution to a better treatment for Chagas chronic patients. Please see its objectives below :
Main objective
• Obtain a more effective, better tolerated and cheaper formulation of a drug with trypanocidal activity to cure Chagas disease
Specific Objectives
• Obtain results of pharmacokinetics of new formulations
• Assess trypanocidal activity of new formulations in vitro and in animal model
• Involve partners, research and industry in endemic countries to promote technology transfer and promote in-site solutions at cheaper cost.
The foreseen results of this project would have firstly an impact on the better comprehension and control of the SUVs behavior as drug delivery nanodevices for the specific APIs to be conjugated. If this conjugation is successful, further impacts are expected dealing with technology transfer issues, such as scale-up of the corresponding SUVs preparation methodology and its implementation at industrial scale.
Apart from including stong participation from endemic countries's institutions, the consortium also involves private companies, thus enabling the participation of all the key actors of the chain to confront and control better Chagas disease. The innovative approach, through the new developed nano- and microparticles based formulations will have an important impact on the safety of the medicament since the therapeutic efficacy will increase and consequently the doses needed and the incidences caused by adverse effects will be reduced.
Champ scientifique
Appel à propositions
FP7-HEALTH-2012-INNOVATION-1
Voir d’autres projets de cet appel
Régime de financement
CP-FP - Small or medium-scale focused research projectCoordinateur
08007 Barcelona
Espagne